Virus inactivating cloth

FIELD: chemistry.

SUBSTANCE: disclosed cloth is capable of inactivating viruses falling thereon even in the presence of lipids and proteins regardless of whether or not the viruses have an envelope. The cloth is capable of inactivating viruses falling thereon and includes a cloth base and fine particles of a monovalent copper compound and/or iodide fine particles, wherein the fine particles of a monovalent copper compound and/or iodide fine particles are deposited on said cloth base. The fine particles of the monovalent copper compound are particles of at least one of the following group: chloride, acetate, sulphide, iodide, bromide, peroxide and thiocyanate. The cloth is capable of inactivating different types of viruses. The viruses are inactivated even in the presence of lipids and proteins.

EFFECT: enabling virus inactivation.

14 cl, 3 dwg, 4 tbl, 13 ex

 

The technical field to which the invention relates.

The present invention is a canvas inactivating viruses, in particular the invention relates to a cloth inaktiverade viruses capable of inactivating various beyond the scope of viruses even in the presence of lipids and proteins regardless of the presence of these membrane proteins. The level of technology.

In recent years there have been reports of deaths caused by the infection of new viruses such as SARS virus (SARS, Severe Acute Respiratory Syndrome) and avian influenza. At the present time in connection with the development of the ability of viruses to transfer and mutations the world is faced with the risk of "pandemic" that is the epidemic of viral infection throughout the world, and there was an urgent need to respond. To resolve this problem quickly developed antiviral drugs on the basis of vaccines. However, vaccines have their own specifics and can only prevent infection by specific viruses. In hospitals, nosocomial infection is a serious problem that is also seen as a social problem. Nosocomial infection is a contagious infection with MRSA (methicillin-resist Staphylococcus aureus) bring to the hospital carriers or sick or infected with the MRSA strain as a result �terion of antibiotics. Such contagious infection is transferred from one set of patients to other patients and medical staff through robes, pajamas, blankets, or medical equipment or other equipment, such as condiioner. Consequently, there is a strong need for the development of antivirusnika means having bactericidal and antiviral effects for various viruses and bacteria.

To solve the above problems, developed a cloth inactivating viruses using a composite structure, made of polymers containing inorganic porous crystals that contain antibacterial metal ions such as silver ions or copper ions (Patent literature 1). The virus inactivating agents containing dissolved iodide-cyclodextrin clathrate compounds have also been described (Patent literature 2, 3, and 4). A list of references. Patent literature

Patent literature 1: lined patent application of Japan No.2006-291031

Patent literature 2: lined patent application of Japan No.2006-328039

Patent literature 3: lined patent application of Japan No.2007-39395

Patent literature 4: lined patent application of Japan No.2007-39396

Disclosure of the invention.

A technical problem.

Methods of making polymers containing inorganic porous crystallinity for fibrous tissues. However, such methods are not applicable to coatings and paintings that do not use fiber and inorganic materials. The virus inactivating agent using iodine is water-soluble. Therefore, in the impregnation of the fabric or cloth so the virus inactivating agent, if the cloth or a cloth moistened with water, the components dissolved in the water.

Viruses are classified into those that do not have a shell, such as noroviruses and those that have a shell, such as influenza viruses. Although the drug is able to inactivate the virus in the shell, such drug may be ineffective for intercourse to viruses without the shell. When the virus inactivating canvas is applied to a bandage or used, for example, as a surgical protective armband, lipids and proteins contained in blood or saliva, can stick to inactivating the canvas due to the fact that the product is in contact with the mouth and nose of an infected patient. Therefore, it is required that the virus had been inactivated even in the presence of lipids and proteins. However, this condition is not in the aforementioned patent literature.

To solve the above described problems, the present invention is a fabric that can inactivate various strikes it viruses even in the presence of lipids and proteins and independently �t the presence of these membrane proteins. The solution to the problem.

The first aspect of the present invention is a canvas inactivating the virus is able to inactivate viruses getting on it, characterized by having a base cloth and the fine particles of compounds of monovalent copper and/or fine particles of iodine and micronized particles of a compound of monovalent copper and/or fine particles of iodine applied on the basis of paintings. In the present description under the virus inactivating canvas refers to the canvas, able to inactivate viruses (umenshaetsya invasive ability of viruses and deactivate them). Therefore the idea of the virus inactivating paintings is to attach to the paper base web of cloth for the purpose of inactivation of viruses. In the present invention the expression: the ability to inactivation of viruses and anti-virus capability are used with the same meaning.

The second aspect of the invention is a canvas inactivating viruses in accordance with the first aspect, characterized in that fine particles of compounds of monovalent copper particles are at least one of the following groups: chloride, acetate, sulfide, an iodide, a bromide, a peroxide, an oxide, and thiocynate.

The third aspect of the invention is a canvas inactive�abuser viruses in accordance with the second aspect, characterized in that fine particles of compounds of monovalent copper particles are at least one of the following groups: CuCl, CuOOCCH3, CuI, CuBr, Cu2O, Cu2S, and CuSCN.

A fourth aspect of the invention is a canvas inactivating viruses in accordance with the third aspect, characterized in that the fine particulates iodine compounds represent particles of at least one of the following groups: CuI, AgI, SbI3, IrI4, GeI2, GeI4, SnI2, SnI4, TiI, PtI2, PtI4, PdI2, BiI3, AuI, AuI3, FeI2, CoI2NiI2, Zni extension2, HgI, and InI3.

A fifth aspect of the invention is a canvas inactivating viruses in accordance with any one of aspects one through four, characterized in that fine particles of compounds of monovalent copper and/or fine particles of iodine retained on the canvas by the group of other inorganic fine particles fixed to the substrate via chemical ring of the silane monomer and/or polymerization product of the silane monomer.

The sixth aspect of the invention is a blanket for the bed, is manufactured using virus inaktiverade fabric, in accordance with any one of aspects from the fourth to the fifth.

The seventh aspect and�gaining is a protective suit, manufactured using virus inaktiverade fabric, in accordance with any one of aspects from the fourth to the fifth.

The eighth aspect of the invention is a glove made with the virus inaktiverade fabric, in accordance with any one of aspects from the first to the fifth.

The ninth aspect of the invention is a medical napkin, showmenu using virus inaktiverade fabric, in accordance with any one of aspects from the first to the fifth.

The tenth aspect of the invention is a medical cap, fabricated using virus inaktiverade fabric, in accordance with any one of aspects from the first to the fifth.

The eleventh aspect of the invention is a Shoe covers that are manufactured using virus inaktiverade fabric, in accordance with any one of aspects from the first to the fifth.

The twelfth aspect of the invention is a filter manufactured using the virus inaktiverade fabric, in accordance with any one of aspects from the first to the fifth.

The thirteenth aspect of the invention is a surgical tape that are manufactured using virus inaktiverade fabric, in accordance with any one of aspects from the first to the fifth.

The fourteenth aspect of the invention is a gauze manufacturer�Lenno using virus inaktiverade paintings in accordance with any one of aspects from the first to the fifth.

The fifteenth aspect of the invention is a Wallpaper made with the virus inaktiverade fabric, in accordance with any one of aspects from the first to the fifth. The technical result of the invention.

In the framework of the present invention proposes a canvas that is easily inactivate various viruses, hitting its surface even in presence of proteins, for example, drops of saliva and blood.

Brief description of the drawings

Fig.1 is a cross section of a cloth inactivating viruses in the first variant implementation.

Fig.2 is a cross section of a cloth inactivating viruses in a second embodiment of the implementation.

Fig.3 is a cross section of a cloth inactivating viruses in a third variant of the implementation.

The implementation of the invention.

Next, with reference to Fig.1 is described first variant implementation.

Fig.1 shows a view of part of an enlarged cross section of a leaf inactivating viruses 100 in the first embodiment of the presented invention. Inorganic fine particles, having the ability to inactivate viruses (the virus inactivating particles), are connected by a connecting component with the surface of the base cloth 1, used � as substrate.

In the first embodiment of the present invention, the silane monomer or oligomer obtained by polymerization of the silane monomer used as the binder component, for the reason described later. Therefore, as an example, for the purpose of understanding, the virus inactivating fine particles 2 are associated with surface 1 chemical link 5 through the silane monomer (or a polymerization product of the silane polymer). In this case, under the dimmer refers to the oligomer. In this embodiment, the implementation uses a reinforced material 4 to secure the virus inactivating fine particles 2 with the base fabric 1, as shown in figure 1. Reinforced material is added only if necessary, secure the virus inactivating fine particles 2 with the base fabric 1.

In the first variant of implementation, the virus inactivating fine particles 2 are compounds of monovalent copper and/or fine particles of iodine and can inactivate viruses as if they have shells, so in its absence.

Therefore, as a first embodiment of the invention is considered an antiviral agent comprising at least one of the following inorganic fine particles from the group consisting of fine particles of compounds�Oia monovalent copper and/or fine particles of iodine. The virus inactivating particles 2 in the first embodiment, has the potential to inactivate viruses even in the presence of proteins and lipids.

Currently, the mechanism of inactivation of viruses todisperse particles is unclear. It is anticipated that this mechanism works as follows. Upon entry inactivating the virus fine particles 2 in contact with moist air or drops, some fine particles 2 is subjected to oxidation-reduction reactions. This affects the surface electric charge, either a membrane protein or DNA viruses getting onto the canvas 100 in the first embodiment of implementation, the resulting viruses are neutralized.

To the size of inactivating the virus of fine particles does not impose special restrictions, so ask them can a specialist in this field. However, the average particle diameter is preferably greater than or equal to 1 nm and less than 500 nm. If the average particle diameter of less than 1 nm, inactivating the virus fine particles lose their physical stability and are glued with each other. Therefore, in this case more difficult to evenly place the particles on the filter element 1. If the average particle diameter exceeds 500 nm, the adhesion between the particles and the filter element 1 is lower than in the case where the average particle diameter of p�falls in the range indicated above. The average particle diameter in this case is the average volume diameter.

Type inactivating the virus fine particles 2 serving as the active ingredient also does not impose special restrictions.

However, preferably, the compound of monovalent copper particles were chloride, acetate (compound acetate), sulfide, iodide, bromide, peroxides, oxide, thiocynate or their compositions. More preferably, the compound fine particles of compounds of monovalent copper particles was at least selected from the following group: CuCl, CuOOCCH3, CuI, CuBr, Cu2O, Cu2S, and CuSCN. It is preferable that fine particles of iodine particles were, at least, particles, selected from the following group: CuI, AgI, SbI3, IrI4, GeI2, GeI4, SnI2, SnI4, TlI, PtI2, PtI4, PdI2, BiI3, AuI, AuI3, FeI2, CoI2NiI2, Zni extension2, HgI, and InI3. More specifically, in the first variant of implementation, for fixing to the virus inactivating canvas can be used only one type of particle 2, or for fixing to the base fabric 1 can be used two or more types of particles.

In the first embodiment of the fine virus inactivating particles 2 are attached to the surface of the Foundation cloth 1 using the binder. As described above, Fig.1, the binder component is used, the silane monomer (or its polymerization product). However, there may be used any other binder. Used swesome component is not imposed special restrictions. For example, can be used next svatusa substances: synthetic polymers such as polyester polymers, amino polymers, epoxy polymers, polyurethane polymers, acrylic polymers, water-soluble polymers, polymers based on vinyl, fluorinated polymers, silicone polymers, polymers on cellulose ASNOVA, phenolic polymers, kelanie polymers and toluene polymers and natural polymers, such as drying oil, such as castor oil, linseed oil and Tung oil.

In the present variant implementation, the silane monomer 3, or an oligomer obtained by polymerization of the silane monomer used as the binder comonent. Due to the fact that these monomers and oligomers are low molecular weight, they do not cover the fine virus inaktiverade particles 2 completely and it is unlikely that it will be prevented by contact between fine particles and viruses infesting the basis of paintings 1.

Consequently, the use of the silane monomer 3 (or its polymerization product) as a binder�about substance promotes effective inactivation of viruses.

Due to the fact that the silane monomer is durable binder uluchshaetsya adhesion of the Foundation cloth 1 and the fine virus inactivating particle 2 is more stably held on the basis of leaf 1.

The specific examples of the silane monomer used for the canvas inactivating viruses 100 in the first variant of implementation, including a silane monomers represented by the General formula X-Si(OR)n(n is an integer from 1 to 3). In this case X represents a functional group that interacts with organic matter: for example, vinyl group, epoxy group, sterinova group, methacrylic group, akilattirattu, an isocyanate group, a polysulfide group, an amino group, mercaptopropyl and chorograph. Each group OR represents a hydrolyzable alkoxygroup, such as a methoxy group or an ethoxy group, with three functional groups in the silane monomer may be the same or different. These alkoxygroup that include methoxy - and ethoxypropan, hydrolyzed with the formation of silanol groups. Known for high reactionary such silanol group, vinyl group, epoxy group, a styryl group, methacrylic group, akilattirattu, isocyanate groups and functional groups having unsaturated bond, and other such. In particular, in the canvas in inactivating�eng 100, in the first variant of implementation, inactivating the virus fine particles are strongly held on the surface of the Foundation cloth 1 chemical bonds 5 by the silane monomer with a high reactionary.

Examples of the silane monomer, represented by the above General formula include: vinyltrichlorosilane, VINYLTRIMETHOXYSILANE, vinyltriethoxysilane, VINYLTRIMETHOXYSILANE,

N-β-(N-vinylbenzoate)-γ-aminopropyltrimethoxysilane, hydrochloride

N-(vinylbenzyl)-2-aminoethyl-3-aminopropyltrimethoxysilane,

2-(3,4-epoxycyclohexyl)ethyltrimethoxysilane,

3-glycidoxypropyltrimethoxysilane,

3-,

3-glycidoxypropyltrimethoxysilane, para-sterlitamatskaya,

3-,

3-,

3-,

3-methacryloxypropyltrimethoxysilane,

3-acrylonitrilebutadiene,

3-isocyanatopropyltrimethoxysilane,

bis(triethoxysilylpropyl)tetrasulfide,

3-aminopropyltrimethoxysilane, 3-aminopropyltriethoxysilane,

3-triethoxysilyl-N-(1,3-dimethylbutylamino)Propylamine,

N-phenyl-3-aminopropyltrimethoxysilane,

N-2-(aminoethyl)-3-aminopropyltrimethoxysilane^

N-2-(aminoethyl)-3-aminopropyltrimethoxysilane,

N-2-(aminoethyl)-3-amino�openthreadtoken,

3-,

3-mercaptopropionylglycine,

N-phenyl-3-aminopropyltrimethoxysilane, special aminosilane, 3-ureidopropionic, 3-chloropropionitrile, tetramethoxysilane the tetraethoxysilane, methyltrimethoxysilane, methyltriethoxysilane, dimethyldiethoxysilane, phenyltriethoxysilane, hexamethyldisilazane, hexyltrimethoxysilane, decyltrimethoxysilane, siloxanes containing hydrolyzable groups, oligomers containing peralkaline group, methylhydrosiloxane and Quaternary ammonium salts of silicon.

In the number of oligomers on the basis of silane are commercially available oligomers COP-893, KR-500, X-40-9225, KR-217, KR-9218, KR-213 and KR-510, which are the products of the company Shin-Etsu Chemical Co., Ltd. These oligomers on the basis of silane may be used individually, as mixtures of two or more of them or as a mixture with one, two or more of the above silane monomers.

As explained above, in the fabric inactivating viruses 100 in the first embodiment of implementation, the virus inactivating fine particles 2 are calculated on the basis of a cloth using a silane monomer or oligomer with at least part of the exposed surface of the particles.

Consequently, the likelihood of reaching the contact surface inactivating virus 100 virus and bacteria with a virus inactive�sponding toondisney particles 2 may be higher than in the case when inactivating the virus fine particles fixed on the base fabric 1 by using such a binder as the polymer. It can effectively neutralize the virus even when using small amounts of inactivating the virus fine particles 2.

Inactivating the virus fine particles secured to the base fabric 1 chemical bonds with the silane monomer or oligomer, so the number of inactivating the virus of fine particles, which are separated from the base fabric 1, is significantly lower than in the case when these particles are covered and secured, for example, a conventional binder. Thus, the canvas inactivating viruses 100 of this embodiment is able to maintain its antivirus properties for a longer time. Inactivating the virus fine particulates can be retained through the condensation reaction, the amide linkages, hydrogen bonds, ionic bonds, van der Waals forces, or physical adsorption. This effect can be achieved by selecting a suitable silane monomer.

In the first variant of implementation there are no particular restrictions on the method of retention of inactivating the virus fine particles 2 on the basis of leaf 1, and this method may choose a specialist about this�lusty. For example, the respective fine particles can be dispersed on the basis of leaf 1. Inorganic fine particles may be contained in the form of complexes of particles with two - or three-dimensional structure. In particular, inactivating the virus fine particles can be aggregated in the form of points, islets or thin film. If inactivating the virus fine particles exist in the form of three-dimensional systems, they contain particles that are associated with the base of the blade 1 through the silane monomer or oligomer 3(such particles are called inactivating fine particles of virus 2A), and particles associated with the base fabric 1, at least, by inactivating the virus fine particles 2A.

Preferably, the inactivating virus fine particles 2 were held on the basis of the fabric 1 in the form of three-dimensional systems, since the surface of the base fabric 1 is formed a large number of small irregularities that prevent the adhesion of dust and similar substances to the base fabric 1. The suppression of the adhesion of dust and similar substances allows the blade 100 save antivirus properties for a longer time.

In the canvas inactivating viruses 100 in the first variant of implementation, in addition to inactivating the virus fine particulates can �use of the functional material to make the fabric 100 desired properties. This functional material can stick to the surface of the base fabric 1.

Examples of functional material composed of other antiviral agents, antibacterial agents, antifungal agents, antiallergic agents and catalysts. Such a functional material may be fixed on the basis of leaf 1, inactivating the virus fine particles, etc with binder. As in the case of inactivating the virus fine particles, the functional material may be associated with the base fabric 1 by means of chemical bonds between the silane monomer or oligomer that is associated with the surface of the functional material.

Regardless of whether linked or not functional material with a basis of paintings, inactivating the virus fine particles 2 can be connected with the base fabric using additional reinforcing filler (filler paved) 4 in addition to the silane monomer or oligomer 3, as shown in figure 1. In dalneishem description materials related to the Foundation fabric 1 (such materials include virus inaktiverade of fine catici 2, the silane monomer 3 (or oligomer 3), and the like) will be referred to as compositions for holding the basics.

Specialist in the art can appropriately ask to�number inactivating the virus fine particles, held by the blade 100 in the first variant of implementation, with consideration of the purpose and method of use of the web, and also the size of the fine particles. The number of inactivating the virus fine particles, comprising means for holding bases, preferably is from 1 to 80 percent by weight of the total weight of substances, and even more preferably from 5 to 60 percent by weight. If the number of inactivating the virus of the fine particles is less than 1 percent by weight, the antiviral activity is lower than when this amount falls within the above range. If this amount exceeds 80% by mass, antiviral activity is not much different from when this amount falls within the above range. In addition, the binding properties of the oligomer formed by the condensation reaction of the silane monomer, are reduced and, consequently inactivating the virus fine particles are separated from the base fabric 1 is easier than when the amount is within the above range.

Next will be described the base fabric 1, which are virus inationwide particles 2. In the first embodiment of the invention for the fabric may be any basis under the condition that the base of the blade 1 can be chemically linked to monomer� silane or its oligomer 3, at least part of the surface of the base fabric 1. Therefore, in the first variant of implementation, no particular limitation is not imposed on other properties of the Foundation cloth 1.

There is also no particular limitation is not imposed on the form of Foundation cloth 1, with the proviso that the base has a corresponding leaf shape.

An example of a Foundation cloth 1 having the surface, which can be chemically bound to the silane monomer or oligomer 3, is the basis of paintings 1, at least part, which consists of any of a variety of polymers, synthetic fibers, natural fibers such as cotton, hemp, silk, Japanese paper, produced from natural fibers.

In the manufacture of a polymer surface or a fully bases of the leaf 1 use synthetic or natural polymer.

An example of such a polymer is a thermoplastic polymer such as polyethylene polymers, polypropylene polymers, polystyrene polymers, ABS polymers, AS polymers, EVA polymers, polymethylpentene polymers, polyvinyl chloride polymers, polyvinylidene chloride polymers, polymethyl arcrylic polymers, polyvinyl acetate polymers, polyamide polymers, polyimide polymers, polycarbonate polymers, polyethylene terephthalate polymers, polybutylene terephthalate polymers,Polyacetal polymers, polyacrylate polymers, polysulfone floor�measures polyvinylidene fluoride primary, Vectran (registered trademark), and PTFE (polytetrafluoroethylene); biodegradable polymers such as polylactic polymers, polyhydroxybutyrate polymers, modified starch polymers, polycaprolactone polymers, polybutylene succinate, polybutylene adipate terephthalate polymers, polybutylene succinate terephthalate polymers, and polyethylene succinate polymers; thermosetting polymers such as phenolic polymers, carbamide polymers, melamine polymers, unsaturated polyester polymers, diallyl phthalat polymers, epoxy polymers, epoxy acrylate polymers, silicone polymers, acrylic-urethane polymers, and urethane polymers; elastomers such as silicone polymers, polystyrene elastomers, polyethylene elastomers, polypropylene elastomers, polyurethane elastomers; and natural polymers such as frosting.

In the first variant of implementation izobreteniya, the surface of the base fabric 1 may be formed of luogo metal such as aluminum, stainless steel, iron and Neorganicheskie, such as glass or ceramic, provided that can be formed chemical bonds 5 with the silane monomer or oligomer.

In this case, as in the case of polymeric substrates, for example, unsaturated bond or a reactive functional group of the silane monomer 3 m�can react with the hydroxy group on the metal surface through polymerizatio described below for the formation of chemical bonds 5. In this case, virus antivirusa fine particles 2 can be attached to a metal base fabric 1. However, when a functional group capable of forming a chemical link 5 are introduced on the surface of the base fabric 1 by means of a silane monomer, a monomer of titanium or the like substance, the virus inactivating fine particles 2 are held more firmly. Examples of functional groups that occur in their monomer of silane and introduced into the surface of the base fabric 1 are vinyl group, epoxy group, stillove group, methacrylate group, aryloxy group, an isocyanate group, and thiol group.

Basis 1 virus inactivating cloth 100 in the first variant of implementation will be described in more detail. For example, the base fabric in accordance with the first varianta implementation can be made from fibers. More specifically, the base fabric 1 may be of textile fabric, knit fabric, neklanova material, and the like. Consequently, the virus inaktiverade the canvas can absoltutely for masks, caps, Shoe covers, filters for air conditioners, filters for air purifiers, filters, blowers, filters for vehicles, filters for air conditioning, filters for ventilation, heat and lagoon�of enikov (HIM), medical tissues (medical protective fabrics and dressings, surgical sheets, bands, Marley, Wallpaper, clothing, duvet covers, nets, and other such as protivomaskitnye mesh.

Examples of fibers that make up the base of the blade 1 are:

polymeric materials such as polyester, polyethylene, polypropylene, polyvinyl chloride, polyethylene terephthalate, polybutylene terephthalate, polytetramethylene terephthalate, nylon, acrylic, polytetrafluoroethylene, polyvinyl sprit, Kevlar, polyacryla acid, polymethyl metacrylate, viscosia, Cupra, Tencel, Polynosic, acetate, triacetate, cotton, hemp, wool, silk, and bamboo; and metals such as aluminum, iron, pravesha steel, brass, copper, tungsten, and titanium.

An additional element, such as film or sheet, can be laid on the surface of the virus inaktiverade cloth 100 in the first embodiment of implementation. As a result, the virus inactivating sheet can, for example, be water resistant. With such properties can be manufactured high-tech protective suits and medical gloves to prevent the spread of viruses and infected blood. Can also be made of woven bandages and blankets for hospitals and hospital personnel.

Permeable film or sheet impervious to water but pervious to air(moisture), preferably used for laying on the surface of the fabric, providing comfort for its user.

More specifically, depending on the purpose, use film or sheet on the basis of common commercially available products.

The gluing substance and any such may be deposited on at least one main surface of the virus individualo cloth 100 in the first embodiment, so that the user can easily stick the sheet to the mask, wall or floor. More specifically, the virus inactivating sheet can be made by connecting a conventional blade and the virus inactivating fabric in accordance with the first variant implementation.

Executing the basics of blade 1 in the first variant implementation is not limited vodopronitsaemoy structure and can impede the flow of air, i.e. may have a protective function. More specifically, the base fabric 1 can be made in the form of a film using any of the following materials: polymers such as polyester, polyethylene, polyamide, polyvinyl chloride, polyvinylidene fluoride, polyvinyl alcohol, polyvinyl acetate, polyamide, polyamide imide, polytetrafluoroethylene, and tetrafluoroethylene-ethylene; polymer sheets, such as polycarbonate polymer sheet and film, vinyl chloride sheets, fluorocarbon poliomyelitis, polyethylene sheets, silicone polymer sheets, nylon sheets, ABS sheets, and carbamate leaves; and metals such as titanium, aluminum, stainless steel, magnesium and brass.

To make the base surface of the canvas vozduhonosnykh properties preferred advance hydrophilicity, which is carried out by processing the surface by corona discharge, atmospheric plasma or flame to increase the adhesion of the fine virus particles and inactivating the basics of blade 1. Further, if the sheet material is made of metal, it is preferred to remove the emulsion for lubrication, corrosion products, and the like, the adhesive associated with the surface is carried out, for example, by means of a solvent, acid or alkali. In addition, the surface of the base fabric can also be painted, it can be applied pattern and the like.

The virus inactivating fabric 100 fine with a virus inactivating particles having vozduhonosnye properties, can be used in various fields, for example include: Wallpaper, Windows, blinds, coverings for tables, bags for food storage, film for food, chahla for keyboards, touch panels and covers for them, medical wipes, materials for internal finishing of buildings (like hospitals), materials for internal finishing trains and automobiles, sheet material �La hire, seat covers, the equipment used when working with viruses, gryazeustoychivy sheet materials for doors and flooring, masks for breathing apparatus and their parts.

As described, to the base of the blade 1 can be added reinforcing material 4 for holding a particulate virus inactivating particle. Any of the above described type of polymer can be used as a reinforcing material. The silane monomer other than the compound of the silane monomer 3, can be used as a reinforcing material.

The following is a detailed description of the method of manufacturing the virus inactivating cloth 100 in the first variant of implementation, which are inactivating the virus fine particulates.

Initially, at least one substance from among compounds of monovalent copper, and iodine. Then the material is ground to particles of the order of micrometers using jet mills, hammer mill, ball mill or vibrating mill to obtain inactivating the virus fine particles. The grinding is performed without any restriction by any of wet and dry methods.

Then chopped inactivating the virus fine particles are dissolved, for example, water, methanol, ethanol, MEK, acetone, xylene or toluene. In SL�tea needed at this stage of production, dissolved in a mixture also reinforcing material 4 and functional materials. Then if necessary add a dispersing agent such as surfactant, and the resulting mixture was dispersed and pulverized by using a device such as a bead mill, ball mill, sand mill, roll mill, a vibrating mill or a homogenizer. Then the dispersion is added to the silane monomer 3 to form a slurry containing fine virus inactivating particles 2. Upon receipt of a suspension as described above, the diameter of inactivating the virus fine particles and the second inorganic fine particles is reduced, resulting in the first inactivating the virus fine particles 2 are arranged on the surface of the base fabric 1, without excessive gaps between the particles 2. This allows to increase the density of the inactivating virus fine particles, thus achieved a good anti-virus properties.

The dispersion can be prepared using such methods as dipping, spraying, roller application, application squeegee, coating by centrifuging, gravure printing, offset printing, screen printing or ink jet printing. If necessary, the solvent removed by nahrawan�I and drying and other similar methods. Then the functional group on the surface of the Foundation cloth 1 is chemically bind the silane monomer (formation of chemical bonds 5)by graft-polymerization with the use of re-heating or graft-polymerization by irradiation of infrared rays, ultraviolet rays, electron beam or radiation rays such as γ-rays. During the graft-polymerization, the virus antivirusa fine particulates are associated with each other through the silane monomer or oligomer.

Then, if necessary, in accordance with the first variant of implementation, the film or adhesive bonded to a base fabric 1, e.g., hot rolling.

As described above, the virus inactivating cloth 100 in the first embodiment of implementation protects against various types of viruses, irrespective of the type of the genome and the presence of the virus shell. Among such viruses include: rhinoviruses, poliovirus, virus aphthous fever, rotaviruses, noroviruses, enteroviruses, hepatovirus, Astrovirus, sapovirus, the hepatitis E virus, influenza viruses types A, b and C, parainfluenza, mumps, measles, metapneumovirus human respiratory syncytial virus infection, Nipah virus, Hendra, yellow fever, dengue virus, Japanese encephalitis virus, West Nile virus, hepatitis viruses In the IP, the viruses of Eastern and Western equine encephalitis virus o Nyong-Nyong, rubella virus, Lassa virus, Junin, Machupo, Guanarito, Sabia, virus Crimean-Congo hemorrhagic fever virus phlebotomus fever, Hantaviruses, virus Hantavirus pulmonary syndrome (Sin Nombre), rabies virus, Ebola virus, Marburg virus, Lyssavirus, T-lymphotropic virus human, human immunodeficiency virus, human coronavirus, SARS coronavirus (SARS), human parvovirus, the virus polyoma, human papilloma virus, adenovirus, herpes viruses, the varicella-zoster virus, Epstein-Barr, cytomegalovirus, the virus of human smallpox, Monkeypox virus, vaccinia virus, molluscum contagiosum virus and parapoxvirus.

Using the virus inactivating cloth 100 in the first embodiment of the viruses neutralized even in the presence of lipids and proteins, which appear, for example, as a result of falling drops.

Thus, with the help of a cloth 100 in the first variant of implementation, it is possible to inactivate falling on it viruses. Therefore, the wearing of a cloth to prevent virus infection and suppress the spread of the virus from an infected person. In addition, this reduces the likelihood of secondary infection due to contact with used cloth 100. (Second variantvalue)

Next will be described the virus inactivating cloth 100 in the second variant of implementation. Fig.2 shows a cross section of the virus inactivating cloth 100 in the second embodiment of the implementation.

In the fabric 100 of the second embodiment, in addition to inactivating the virus a particulate matter (hereinafter, the first inorganic fine particles) on the basis of the fabric 1 are held the second inorganic fine particles 6 used as an additional fine particles. In the second embodiment of the second inorganic fine particles 6 together with the first inorganic fine particles 2 form aggregates of the inorganic fine particles with two - or three-dimensional structure. In other words, in the second variant of implementation through the blade 1 is held aggregates of inorganic particles 2 containing the first and second inorganic fine particles. Fig.2, shows a reinforcing material 4 is used to associate the first inorganic 2 and the second inorganic fine particles with the base fabric 1. However, the addition of a reinforcing material 4 in the first embodiment of implementation is not mandatory. Elements similar to elements in the first variant of implementation, have the same reference designators and their OPI�R omitted.

The second inorganic fine particles 6 are connected with the base of the blade 1 through the silane monomer or oligomer and form a chemical bond 5 through the silane monomer or oligomer 3. Thus, in the second embodiment of the first inorganic fine particles 2, which serve as inactivating the virus fine particles, associated with the base fabric 1 and the second inorganic fine particles 6 through the silane monomer or oligomer 3 and are arranged on the filter element 1. In the second variant of implementation of the first inorganic fine particles 2 held on the base fabric 1, connecting with groups of the second inorganic fine particles 6, forming chemical bonds 5 with each other through the silane monomer or oligomer 3. This prevents separation of the first inorganic fine particles 2 from the base fabric 1 is not only chemical, but also by the physical links. In the virus inactivating canvas 100 of the second variant of implementation, the Department of inactivating the virus fine particles 2 is prevented more effectively compared with the first embodiment. This allows you to retain the ability to inactivate viruses for a longer time.

In the second embodiment is carried out�of tvline groups of the second inorganic fine particles, connected with each other through the silane monomer, prevent separation of the first inorganic fine particles from the base fabric 1. Therefore, the first inorganic fine particles 2 may not form bonds with the second inorganic fine particles 6 and the base of the blade 1 through the silane monomer or oligomer 3.

In the virus inactivating canvas 100 of the second embodiment of the first inorganic fine particles 2, which serve as inactivating the virus fine particles, associated with the second inorganic fine particles 6 and the base of the blade 1 through the silane monomer and oligomer 3 and, accordingly, the surface of the first inorganic fine particles 2 is open, as in the case of the first variant implementation. Thus, it is possible to increase the probability of contact of the virus gets to the surface of the blade 100, with inactivating fine particles of virus 2 as compared to the case when inactivating the virus fine particles 2 are fixed on the basis of a cloth 1 using the usual binders that can effectively inactivate the virus even while using a small amount of fine particles.

On the second inorganic fine particles 6 in with�testii the second option, the implementation is not imposed special restrictions, provided that they are linked to the silane monomer or oligomer 3, and the person skilled in the art can select the appropriate second inorganic fine particles. In particular, it is possible to use a non-metallic oxides, metal oxides, complex metal oxides, nitrides, carbides, silicates and mixtures thereof. The second inorganic fine particles may be amorphous or crystalline. Examples of non-metal oxides is silicon oxide. Examples of metal oxides include:

magnesium oxide, barium oxide, barium peroxide, aluminum oxide, tin oxide, titanium oxide, zinc oxide, titanium peroxide, zirconium oxide, iron oxide, iron hydroxide, tungsten oxide, bismuth oxide, indium oxide, gibbsite, boehmite, diaspore, antimony oxide, cobalt oxide, niobium oxide, manganese oxide, Nickel oxide, cerium oxide, yttrium oxide and praseodymium oxide. Examples of complex metal oxides include barium titanate, aluminate of cobalt, plumbat zirconium, plumbat niobium, TiO2-WO3, AlO3-SiO2, WO3-ZrO2, WO3-SnO2CeO2-ZrO2, In-Sn, Sb-Sn, Sb-Zn-In-Sn-Zn, B2O3-SiO2P2O5-SiO2, TiO2-SiO2, ZrO2-SiO2Al2O3-TiO2Al2O3-ZrO2Al2O3-CaO, Al2O3-B2O3Al2O 3-P2O5Al2O3-CeO2Al2O3-Fe2O3, TiO2-ZrO2, TiO2-ZrO2-SiO2, TiO2-ZrO2-Al2O3, TiO2-Al2O3-SiO2and TiO2-CeO2-SiO2. Examples of nitrides include titanium nitride, tantalum nitride and niobium nitride. Examples of the carbides include silicon carbide, titanium carbide and niobium carbide. Examples of silicate adsorbent includes: synthetic zeolites, such as zeolite A, zeolite P, zeolite X and zeolite Y; natural zeolites such as clinoptilolite, sepiolite and mordenite; layered silicate compounds such as kaolinite, montmorillonite, Japanese acid clay and diatomaceous earth; and cyclosilicate compounds such as wollastonite and neptunite. As other examples of phosphate compounds such as tricalcium phosphate, calcium hydrogen phosphate, calcium pyrophosphate, metaphosphate of calcium and hydroxyapatite, activated carbon, and porous glass.

Specialist in the art can appropriately determine the diameter of the second inorganic fine particles 6, for example, in accordance with the purpose of use and method of application of a cloth and a diameter of the first inorganic fine particles 2. From the viewpoint of bond strength with the base fabric 1, the second diameter not�organicheskih fine particles 6 is 500 nm or less, preferably, 300 nm or less.

As described above, the specialist in the art can appropriately determine the diameter of the second inorganic fine particles 6. However, for the same reason as for inactivating virus fine particles, the diameter should preferably be not less than 1 nm.

The following is a detailed description of the method of manufacturing the virus inactivating cloth 100 in the second variant of implementation, which are inactivating the virus fine particulates 2.

First, as in the first variant of implementation, choose at least one substance from the iodide of platinum (II), palladium iodide (II), iodide copper (I) iodide, silver (I) thiocyanate, copper (I), after which the material is ground to particles of the order of micrometers using jet mills, hammer mill, ball mill or vibrating mill to obtain inactivating the virus fine particles. The grinding is performed without any restriction by any of wet and dry methods.

Then chopped inactivating the virus fine particulates mixed with the second inorganic fine particles with which the silane monomer linked by dehydration-condensation, and the mixture is dispersed in a solvent, for example, in�de, methanol, ethanol, MEK, acetone, xylene or toluene. At this stage, in addition to inactivating the virus fine particles and the second inorganic fine particles is associated with the silane monomer in the solvent it is possible to add other substances, for example, a binder component and a functional substance. Then, if necessary add a dispersing agent such as surfactant, and the resulting mixture was dispersed and pulverized by using a device such as a bead mill, ball mill, sand mill, roll mill, vibratory mill or homogenizate. Eventually get a suspension which contains dispersed in it, inactivating the virus fine particles and the second inorganic fine particles. Upon receipt of a suspension as described above, the diameter of inactivating the virus fine particles and the second inorganic fine particles is reduced, resulting in the first inactivating the virus fine particles and the second inorganic fine particles are arranged on the surface of the base fabric 1, which forms the basis 10 of a cloth without excessive gaps between the particles. This allows to increase the density of the inactivating virus fine particles and more firmly secure the group in�contain inorganic fine particles on the surface of the base fabric 1, forming the base 10 of the canvas. Thus achieved a good anti-virus properties that can be maintained for a long time.

The chemical bond between the second inorganic fine particles and the silane monomer can be formed in the usual way. In one example of the method, the silane monomer is added to the dispersion, which is then heated to reflux, allowing the silane monomer to connect with the surface of the second inorganic fine particles by reaction of dehydration-condensation with the formation of thin films of silane monomer. In another example method, the silane monomer is added to the dispersion, which is subjected to grinding to reduce particle size, or the silane monomer is added to the dispersion of the second inorganic fine particles and the resulting dispersion was milled to reduce particle size. Then the solids and liquid are separated from each other

and the separated solid substance was heated at a temperature of 100-180°C, allowing the silane monomer to connect with the surface of the second inorganic fine particles by reaction of dehydration-condensation. The resulting particles are crushed, and then re-dispersed.

In the above-described methods, the number�tvo of the silane monomer to be added to the dispersion depends on the average diameter of the particles and the material of the second inorganic fine particles. However, if the quantity is from 3 to 30 percent by weight by weight of the second inorganic fine particles, the bond strength between the second inorganic fine particles, and the strength of connection between groups of the second inorganic fine particles and a filter element constituting the basis of the 10 paintings in the present invention, does not cause any practical problems. Even after the silane monomer and other similar substances associated with the first inorganic fine particles, the surface of the first inorganic fine particles, remains largely open. In addition, the process of binding may be present an excess of the silane monomer which is not involved in binding.

Continues the description of the method of manufacturing the blade 100 in the second variant of implementation. As in the case with the first embodiment of implementation, the obtained slurry was applied onto the surface of the base fabric 1 by using such methods as dipping, spraying, roller application, application squeegee, coating by centrifuging, gravure printing, offset printing, screen printing or ink jet printing. If necessary, the solvent is removed by heating and drying and other similar methods. Then the functional group on the u�the sur face of the Foundation cloth 1 is chemically bound by graft-polymerization with the use of re-heating or graft-polymerization by irradiation of infrared rays, ultraviolet rays, electron beam or radiation beams, for example, γ-rays, with the silane monomer associated with the surface of the second inorganic fine particles, which faces the surface of the substrate 1 leaf(formation of chemical bonds 5). At the same time, the silane monomers on the surface of the second inorganic fine particles are chemically bound to each other with the formation of oligomer. Simultaneously inactivating the virus fine particulates in contact with the second inorganic fine particles through the silane monomer. When adding binders (other silane monomer) inactivating the virus fine particulates in contact with the second inorganic fine particles and the basis 10 of a cloth by means of a silane monomer and oligomer formed. In this process, inactivating the virus fine particles that have the ability to inactivate viruses, find yourself surrounded by groups of the second inorganic fine particles, whereby you get the base fabric 1, the restraint on its surface inactivating the virus fine particulates. If necessary, after obtaining the Foundation cloth 1 containing on its surface, the virus inactivating fine particles 2, not� applied film or adages in accordance with the second variant implementation.

In the above description, the silane monomer is pre-associated with the second inorganic fine particles, but this method is not unique. Inactivating the virus fine particles, the second inorganic fine particles that are not associated with the monomer of silane, and the silane monomer can be dispersed in the dispersion medium.

The person skilled in the art can determine the required amount of silane monomer. As in the above description, it can be from 3 to 30 percent by weight by weight of the second inorganic fine particles. In the above range, the bond strength between the second inorganic fine particles, and the strength of connection between groups of the second inorganic fine particles and a filter element constituting the basis of the 10 paintings in the present invention does not cause any practical problems. Even after the bonding of the silane monomer and similar substances with the first inorganic fine particles of the surface of the first inorganic fine particles remain sufficiently open. (The third variant of implementation)

Next, with reference to Fig.3 will be described a third embodiment of the present invention, the virus inactivating fabric 100.

Fig.3 schematic� shows an enlarged General view of the virus inactivating canvas in the third variant of implementation. The virus inactivating cloth 100 in the third variant of implementation contains the virus inactivating fine particles attached to the inside of the Foundation cloth 1.

According to a third embodiment of the except the virus inactivating fine particles may also be present other inorganic fine particles 6 that do not have the virus inactivating effect, as for example, in the second variant of implementation. Fig.3 schematically shows an exemplary embodiment with inorganic fine particles 6 that are different from the virus inactivating particle 2. In another embodiment, in addition to the virus inactivating particles are used two or more types of inorganic fine particles.

The size of the virus inactivating particle 2 is not imposed specific limitations. However, it is preferable that the average particle diameter amounted to 3,000 μm or less. Given the fact that the virus inactivating fine particles can fall out of the Foundation cloth 1 under certain conditions of use, preferably, the average size ranged from 1 nm to 1,000 µm.

The virus inactivating fine particles 2 in the third variant of the implementation can be contained in the inner space of the canvas 1 by mixing the particles with, for example, non-woven product made from neck�tion of fibers or a mixed paper, made by mixing pulp with a binder, when these materials are used for making the bases of the leaf 1.

In addition, synthetic fibers and natural fibers, for example fibers forming the nonwoven products are: cotton, hemp, silk, glass, metals, ceramics, cellulose, and carbon fiber. Non-wovens are made in two stages. First, it is made fleecy layer (so-called pile) used as the basis of non-woven products. Then the fibers and the pile in contact with each other, and the layers of cloth are laid on top of each other. Further, in the third embodiment of the virus inactivating fine particles 2 may be either with the fibers during the formation or the superimposition of layers of cloth. Also can overlap layers not containing the virus inactivating fine particles 2.

As a method of manufacture of the pile may be any of the following technologies: dry method, wet method, method centrifuged ligaments. Given the fact that the virus inactivating fine particles should be in a stable state, the preferred dry method without the use of water and heating.

As the method for bonding of the pile may be any of the following technologies: * heat sealing, chemical� bonding, perforation needles, spun bonding, seam gluing and steam-jet method.

To increase the strength of bonding of the pile may contain an adhesive polymer 7. Specific examples of the adhesive polymer 7 are: saturated polyester polymers, unsaturated polyester polymers, polyvinyl alcohol, urethane resin, epoxy polymers, acrylic polymers, alkyl polymers and starch paste.

Mixed paper is used as the base fabric 1, is obtained by treatment of cellulose, in the third embodiment of the invention. Any of the following types of cellulose may be used, including: wood cellulose, polyethylene, cellulose, viscose cellulose cellulose and vinyl. In addition to cellulose can be used one of the following types of organic synthetic fibers or combination of fibers based on polyester, fiber, polyurethane-based, polyamide fiber on the basis of, the fibers of the polyvinyl alcohol, the fibers of the polyvinyl chloride-based, fiber is a polyolefin based fiber on polyacrylnitrile basis.

In the manufacture of paper, to increase strength, cellulose is added the required amount of reinforcing agent such as glass fibers. The mixture is dissolved in water to obtain a liquid suspension, and then the liquid susp�NSIA is filtered using a round-net paper machine. In the third variant of implementation, the virus inactivating particles are added to the unfiltered slurry and, thus, is fixed inside the framework of the canvas.

The present invention is described in detail in all embodiments, but is not limited to these. There are other options. For example, in the first and second embodiment, the virus inactivating particles are retained on the base fabric 1, at the same time they can be the entire canvas. For example, the virus inactivating fine particles can be surrounded by fibers constituting the fabric. The person skilled in the art it is clear that depending on the composition of the base material of the blade and method of manufacture, the particles can be not only on the fabric surface, but also inside neg, even in the first and second variant implementation.

Further, the present invention is described in detail by examples. However, the present invention is not limited only to these examples.

[Examples]

(Study of the antiviral properties by reaction of hemagglutination)

Were investigated the antiviral properties of various materials (positions 1-27). As the test virus used in the influenza virus (influenza A/Kitakyusyu/159/93(H3N2)) cells cultured in dogs kidney (MDCK, Madin-Darby Canine Kidney). The study was conducted using the analysis of inhibition of haemagglutination (ON), �typically used to measure viral titer.

In particular, in phosphate-saline buffer solution (PBS) was prepared by a series of two-fold diluted solutions of the virus, contacting the slurry of one of the mentioned materials, and 50 ml of the prepared solution was added to plastic 96-well plate. Then to each well was added 50 μl of a 0.5 percent solution of blood cells of the chicken. Wells maintained for one hour at 4°C. Then visually determine the degree of sedimentation of red blood cells. The titer was defined as the maximum factor of dilution of the virus solution in which the sedimentation of the virus was observed.

Suspensions were obtained as follows. First, the materials shown in table 1, were dissolved in phosphate-saline buffer solution (PBS) at a concentration of 10 mass% and 1 mass% relative to samples. Then 450 ml of prepared samples were added to 450 ml of the influenza virus with a titer of 256 in two different concentrations. The resulting solutions were subjected to two different reactions at room temperature for 10 minutes with stirring using a rotor for microtubes. In this description under the concentration slurry understand the percentage content by mass of a specific component (for example, iodide or monovalent copper) relative to total 100% by weight com�of onenow, contained in the suspension, including monovalent iodide or copper and solvent. The powder is then precipitated by centrifugation and the supernatant was used as sample. The results of measuring the titer of each sample are shown in Table 2.

Table 1
No. sampleThe name of the materialMolecular formulaThe manufacturer (Seller)Quality-degree
1COPPER (I) IODIDECuIWAKOWAKO 1 degree
2SILVER (I) IODIDEAgIWAKOChemical used s
3ANTIMONY (III) IODIDESbI3Strem chemicals (WAKO)99.90%
4IRIDIUM (IV) IODIDEIrI4Alfa Aesar (WAKO)99.95%
5 GERMANIUM (IV) IODIDEGeI4Alfa Aesar (WAKO)99.999%
6GERMANIUM (II) IODIDEGeI2A1DRICH99.99%
7TIN (II) IODIDESnI2Alfa Aesar (WAKO)99+%
8TIN (IV) IODIDESnI4Strem chemicals (WAKO)95%
9THALLIUM (I) IODIDETlIWAKOOptical use
10PLATINUM (II) IODIDEPtI2Strem chemicals (WAKO)99%
11PLATINUM (IV) IODIDEPtI4Alfa Aesar (WAKO)99.95%
12PALLADIUM (II) IODIDEPdI2
13VIMALA (III) IODIDEBiI3Strem chemicals (WAKO)99.999%
14GOLD (I) IODIDEAuIStrem chemicals (WAKO)(WAKO) 99%
15GOLD (III) IODIDEAuI3ChemPur Feinchemikalien und Forschungsbedarf GmbH (WAKO)
16IRON (II) IODIDEFeI2Aldrich>99.99%
17COBALT (II) IODIDECoI2Aldrich95%
18NICKEL (II) IODIDENiI2Alfa Aesar (WAKO)99.50%
19ZINC (II) IODIDEZni extension2WAKOWAKO 1 degree
20 MERCURY (I) IODIDEHgIWAKOChemical usage
21INDIUM (III) IODIDEInI3Alfa Aesar (WAKO)99.999%
22COPPER (I) CHLORIDECuClWAKOSpecial degree reagent
23COPPER (I) BROMIDECuBrWAKOWAKO 1ST degree
24COPPER (I) ACETATECuOOCCH3TOKYO CHEMICAL INDUSTRY CO., LTD.The REAGENT 98%
25COPPER (I) THIOCYNATECuSCNWAKOChemical usage
26COPPER (I) SULFIDECu2SAlfa Aesar (WAKO)99.5%
27COPPER (I) OXIDECu2 WAKO99.5+%
Note: "WAKO" in the table means "WAKO PURE CHEMICAL INDUSTRIES, LTD.

InI3
Table 2
No. sampleThe name of the materialMolecular formulaON titre
The concentration of the material (mass%)
50.5
1COPPER (I) IODIDECuI832
2SILVER (I) IODIDEAgI3264
3ANTIMONY (III) IODIDESbI31632
4IRIDIUM (IV) IODIDEIrI43264
5WATERPROOF�OF (IV) IODIDE GeI4<2<2
6GERMANIUM (II) IODIDEGeI2<22
7TIN (II) IODIDESnI2<22
8TIN (IV) IODIDESnI4<22
9THALLIUM (I) IODIDETlI3264
10PLATINUM (II) IODIDEPtI2<264
11PLATINUM (IV) IODIDEPtI43264
12PALLADIUM (II) IODIDEPdI2264
13BISMUTH(III) IODIDE BiI3864
14GOLD (I) IODIDEAuI464
15GOLD (III) IODIDEAuI3864
16IRON (II) IODIDEFeI2<2<2
17COBALT (II) IODIDECoI2<28
18NICKEL (II) IODIDENiI2<24
19ZINC (II) IODIDEZni extension2<24
20MERCURY (I) IODIDEHgI3264
21INDIUM (III) IODIDE<2<2
22COPPER (I) CHLORIDECuCl<2<2
23COPPER (I) BROMIDECuBr<232
24COPPER (I) ACETATECuOOCCH3<2<2
25COPPER (I) THIOCYNATECuSCN1664
26COPPER (I) SULFIDECu2S1664
27COPPER (I) OXIDECu2O864
Control sample(phosphate saline buffer solution)128

NOTE 1: "<2" IN the TABLE MEANS "EQUAL to OR LESS THAN the LOWER LIMIT �of SERENIA TITRE "

Note 2: the TEST SAMPLE was MADE AT CONCENTRATIONS OF 0% (ONLY PHOSPHATE SALINE BUFFER SOLUTION)

As can be seen from the test results in Table 2, all of the materials listed under the numbers 1-27, do not have the virus inactivating effect. At 5% concentration, the titer is znachenie 32 and smaller, i.e. 75% of viruses and over had been inactivated. In particular for each of the following materials: GeI4, GeI2, SnI2, SnI4, PtI2, FeI2, CoI2NiI2, Zni extension2, InI3, CuCl, CuBr, and CuOOCCH3obtained a high effect, i.e., inactivation 98.44% of viruses, or more than, which is the lower limit of measurement of the titer in this test. (Making a virus inactivating leaf)

(Example 1)

Powder of copper iodide (I)were used as fine particles with the virus inactivating effect in Example 1.

(CME-503, manufactured by Shin-Etsu Chemical Co., Ltd.), the silane monomer containing a fragment with unsaturated bonds, is subjected to dehydration-condensation in the usual way for covalent bonding of the silane with the surface of the particles of zirconium oxide (PCS, manufactured by Nippon Denko Co., Ltd.), and the resulting particles are used as the second inorganic fine particles. 40 g of a powder of copper iodide (I) and 60 g of the second inorganic�quarter fine particles are initially dispersed in 900 g of ethanol and milled using a bead mill to obtain slurry with an average particle diameter of 105 nm. The average particle diameter in this case is the average volume diameter. Ethanol is added to the obtained dispersion to adjust the solids concentration to 1 mass%. Then, tetramethoxy silane (CMEs-04, manufactured by Shin-Etsu Chemical Co., Ltd.) is added in an amount of 0.3% by mass to obtain a protective solution.

Then, viscose nonwoven fabric (manufactured by KURARAYKURAFLEX Co., Ltd.) a density of 18 g/m2impregnated with the above-mentioned protective solution and dried to obtain a nonwoven fabric with a virus inactivating effect.

(Example 2)

Polyester monofilament mesh fabric 305 mesh (manufactured by NBC Meshtec Inc.)was immersed in a protective solution, made in accordance with Example 1. The excess solution is removed, and the resulting mesh fabric is dried at a temperature of 110°C for one minute. Then mesh fabric was irradiated with electron beam with an accelerating voltage of 20 kV and 50 kGy to obtain a mesh fabric with a virus inactivating effect.

(Example 3)

Powder of copper iodide (I) used in Example 1 as fine particles with the virus inactivating effect and were milled using dry milling, Nano Jetmizer (production company Aishin Nano Technologies CO., Ltd.). The average particle diameter is 170 nm.

SHC900 (a mixture of melamine poly�EPA silicone polymer, alkyd polymer, manufactured by Momentive Materials Japan LLC) was added to isopropanol to increase the concentration of solid content to 5 percent by weight. Powder of copper iodide (I) were milled using a jet mill to obtain a mixture (mixture SHC900 and isopropanol) in the amount of 1% by mass, and the resulting mixture was stirred using a homogenizer to obtain a protective solution.

Then, viscose nonwoven fabric (manufactured KURARAYKURAFLEX Co., Ltd.) a density of 18 g/m2impregnated with the above-mentioned protective solution and dried at a temperature of 100°C to cure the coating, receiving, thus, viscose nonwoven fabric with a virus inactivating effect.

(Example 4)

Polyester film (manufactured by TORAY Industries, Inc.) a thickness of 125 μm hydrophilized corona discharge and coated with a protective solution prepared in Example 1. The resulting film was dried at room temperature to obtain a film with a virus inactivating effect.

(Example 5)

Powder of copper iodide (I) were milled using a jet mill as in Example 3 and added to ethanol in an amount of 2.0% by mass, and tetramethoxysilane (CMEs-04, manufactured by Shin-Etsu Chemical Co., Ltd.) was added to a mixture of a powder of copper iodide (I) and ethanol) in an amount of 0.4 percent by mass. A mixture of d-d�spargonet using a homogenizer for 5 minutes to obtain a suspension.

Viscose nonwoven fabric (manufactured by SHINWA Corp.) density of 20 g/m2immersed in the prepared slurry. Excess slurry was removed and the nonwoven fabric was dried at a temperature of 120°C for 10 minutes to obtain a nonwoven fabric with a virus inactivating effect.

(Example 6)

Powder cuprous iodide as in Example 2 was used as the fine particles with the virus inactivating effect and were milled with an average diameter of 140 nm particles by crushing, Nano Jetmizer (manufactured by Aishin Nano Technologies CO., Ltd.). The crushed particles are fine particles of copper iodide (I) were added to ethanol in an amount of 4.0% by mass, and tetramethoxysilane (CMEs-04, the production of Shin-Etsu Chemical Co., Ltd.) was added to the mixture in the amount of 0.4 percent by mass. The mixture was re-dispersively using a homogenizer for 5 minutes to obtain a slurry. The average particle diameter in this case is the average volume diameter.

Then cotton non-woven cloth with density of 80 g/m2was immersed in the resulting suspension. Excess slurry was removed, and the non-woven fabric was dried at a temperature of 120°C for 10 minutes to obtain wipers with a virus inactivating effect.

(Example 7)

Powder of silver iodide (I) as in Example 2 was used as encoders�s particles with the virus inactivating effect. Then (CME-503, manufactured by Shin-Etsu Chemical Co., Ltd.), the silane monomer containing a fragment with unsaturated bonds, is subjected to dehydration-condensation in the usual way for covalent bonding of the silane with the surface of the particles of zirconium oxide (PCS, manufactured by Nippon Denko Co., Ltd.), and the resulting particles are used as the second inorganic fine particles. 40 g of powder of silver iodide (I) and 60 g of the inorganic fine particles are initially dispersed in 900 g of methanol, pulverized and dispersed using a bead mill to obtain a dispersion. The average diameter of the obtained particles in the dispersion (suspension) is 140 nm. Also in the obtained suspension was added ethanol to bring the solids concentration to 0.5 percent by weight. The average particle diameter in this case is the average volume diameter.

Then the resulting suspension was used for atomization of viscose non-woven cloth with density of 80 g/GP2and then the nonwoven fabric was dried to obtain wipers with a virus inactivating effect.

(Example 8)

Powder thiocynate of copper (I),designated as 25, were used as fine particles with the virus inactivating effect and was crushed with an average diameter part� 120 nm using Nano dry milling Jetmizer (manufactured by Aishin Nano Technologies CO., Ltd.) The crushed fine particles thiocynate copper (1)were added to ethanol in an amount of 4.0% by mass, and tetramethoxysilane (CMEs-04, manufactured by Shin-Etsu Chemical Co., Ltd.) then was added in the amount of 2.0% by mass. The mixture was pre-dispersed using a homogenizer for 5 minutes to obtain a slurry. The average particle diameter in this case is the average volume diameter.

Then, cotton non-woven cloth with density of 80 g/m2was immersed in the prepared slurry. Excess slurry was removed, and the non-woven fabric was dried at a temperature of 120°C for 10 minutes to obtain wipers with a virus inactivating effect.

(Example 9)

100.0 grams of thiocynate of copper (I), designated as 25, were used as fine particles with the virus inactivating effect was pre-dispersed in 900.0 g of ethanol, and the particles were pulverized and dispersed using a bead mill to obtain a dispersion with an average particle diameter of 104 nm.

(CME-503, manufactured by Shin-Etsu Chemical Co., Ltd.), the silane monomer containing a fragment with unsaturated bonds, is subjected to dehydration-condensation in the usual way for covalent bonding of the silane with the surface of the particles of zirconium oxide (manufactured by Phi�we Nippon Denko Co., Ltd.), and the resulting particles are used as the second inorganic fine particles. 100 grams of the second inorganic fine particles are initially dispersed in ethanol, after which these particles are pulverized and dispersed using a bead mill to form a slurry, with an average diameter of 20 nm. The average particle diameter in this case is the average volume diameter.

Mentioned two types of suspensions were mixed in a proportion of 40% by weight dispersion of thiocynate copper and 60 percent by weight of a dispersion of particles of zirconium oxide. Then to the mixture was added ethanol to increase the concentration of solids to 5% by mass.

Then the resulting suspension was sprayed on viscose nonwoven fiber with a density of 80 g/m2and non-woven fabric is dried to obtain the wipers with a virus inactivating effect.

(Example 10)

Powder of copper chloride (I), designated as 22, was used as fine particles with the virus inactivating effect and was crushed with an average particle diameter of 350 nm using a Nano dry milling Jetmizer (manufactured by Aishin Nano Technologies CO., Ltd.). The average particle diameter in this case is the average volume diameter. TL-0511, manufactured by SEKISUI FULLER, was used as a re�active hot melt adhesive, and was added in the form of particles with a signature of jet pistol ALTA, manufactured by Nordson K. K., to obtain a structured fibrous mass with adhesive properties. Then the crushed fine particles of copper chloride (I)came in contact with a fibrous surface structured fibrous mass. The obtained fibrous structural mass was able to react with reactive hot-melt adhesive under conditions of humidity 60% and temperature of 50°C for 4 hours, the result forming the filter.

(Example 11)

Powder of copper chloride (I), designated as 22, was used as fine particles with the virus inactivating effect and was crushed with an average particle diameter of 350 nm using a Nano dry milling Jetmizer (manufactured by Aishin Nano Technologies CO., Ltd.) The crushed fine particles of copper chloride (1)were added to ethanol in an amount of 0.5% by mass, and tetramethoxysilane (CMEs-04, manufactured by Shin-Etsu Chemical Co., Ltd.) in the amount of 0.4 percent by mass. The mixture was pre-dispersed using a homogenizer for 5 minutes to obtain a slurry. The average particle diameter in this case is the average volume diameter.

Then a polyester film (manufactured by TORAY Industries, Inc.) with a thickness of 125 μm was subjected to hydrophilization with crown bit�and was covered with a protective solution, prepared in Example 11, using corona discharge, the resulting film was dried at 110°C for one minute. Then the film was irradiated with electron beam with an accelerating voltage of 200 kV and 50 kGy to obtain a fabric with a virus inactivating effect.

(Example 12)

Powder of copper oxide (I), designated as 27, was used as fine particles with the virus inactivating effect, and was ground with an average particle diameter of 460 nm using dry milling, Nano Jetmizer (manufactured by Aishin Nano Technologies CO., Ltd.). Crushed particles of copper oxide (I) was added methanol in the amount of 4.0% by mass, and tetraethoxysilane (CMEs-04, manufactured by Shin-Etsu Chemical Co., Ltd.) next was added in the amount of 0.4 percent by mass. The mixture was pre-dispersed using a homogenizer for 5 minutes to obtain a slurry. The average particle diameter in this case is the average volume diameter.

Then the resulting suspension was sprayed on viscose nonwoven fiber with a density of 80 g/m2and non-woven fabric is dried to obtain a nonwoven fabric with a virus inactivating effect.

(Example 13)

100.0 grams of copper oxide (I), designated as 21, were used as fine particles with the virus inactivating effect was pre-d�sirgiovanni in 900.0 grammar of ethanol, and the particles were pulverized and dispersed using a bead mill to obtain a dispersion with an average particle diameter of 210 nm.

(CME-503, manufactured by Shin-Etsu Chemical Co., Ltd.), the silane monomer containing a fragment with unsaturated bonds, is subjected to dehydration-condensation in the usual way for covalent bonding of the silane with the surface of the particles of zirconium oxide (PCS, manufactured by Nippon Denko Co., Ltd.), and the resulting particles are used as the second inorganic fine particles. 100 g of the second inorganic fine particles are initially dispersed in ethanol and milled using a bead mill to obtain slurry with an average particle diameter of 20 nm. The average particle diameter in this case is the average volume diameter.

Mentioned two types of suspensions were mixed in a ratio of 40 percent by weight of powdered copper oxide (I) and 60 percent by weight of particles of zirconium oxide. Then to the mixture was added ethanol to increase the concentration of solids to 5% by mass.

Then the paper is based on vinyl chloride (dinoc (registered trademark), manufactured by Sumitomo 3M Limited) with a thickness of 200 μm was subjected to hydrophilization using corona discharge and were covered with a protective solution, prepared�military in Example 13, the resulting sheets were dried at room temperature to obtain a sheet of vinyl chloride cloth with a virus inactivating effect.

(Comparative example 1)

Viscose non-woven fabric with a density of 18 g/m2(manufactured by KURARAYKURAFLEX Co., Ltd.) was used as the nonwoven fabric in comparative example 1.

(Comparative example 2)

A nonwoven sheet of fabric according to Comparative example 2 was manufactured under the same conditions as in Example 1, but without addition of fine particles with the virus inactivating effect.

(Comparative example 3)

Polyester monofilament mesh fabric 305 mesh (manufactured by NBC Meshtec Inc.) was used as a mesh fabric in comparative example 3.

(Comparative example 4)

Mesh fabric in comparative example 4 was manufactured under the same conditions as in Example 2 but without adding fine particles with the virus inactivating effect.

(Comparative example 5)

Non-woven sheet fabric in accordance with comparative example 5 was manufactured under the same conditions, but without addition of fine particles with the virus inactivating effect.

(Comparative example 6)

Polyester film (manufactured by TORAY Industries, Inc.) a thickness of 125 μm was used as filmy Polat� in comparative example 6.

(Comparative example 7)

Filmy fabric in accordance with comparative example 7 was manufactured under the same conditions as in Example 4 but without the addition of fine particles with the virus inactivating effect.

(Comparative example 8)

Cotton nonwoven fabric according to comparative example 8 was produced under the same conditions as in example 8, but without the addition of fine particles with the virus inactivating effect.

(Comparative example 9)

Fusible nonwoven fabric according to comparative example 9 was produced under the same conditions as in example 10, but without the addition of fine particles with the virus inactivating effect.

(Comparative example 10)

The paper web on the basis of vinyl chloride in accordance with comparative example 13 was manufactured under the same conditions as in example 13, but without the addition of fine particles with the virus inactivating effect.

[0132]

(Method of evaluation of antiviral properties in the present invention)

During the measurement of the anti-virus ability of the virus inactivating cloth was used influenza virus (influenza A/Kitakyusyu/159/93 (H3N2)), sown in MDCK cells and used as the virus in the shell, and cat calciumvirus used as an alternative to norovirus and used�th as a virus without the shell.

A sample of a nonwoven fabric or a mesh fabric, used as virus inactivating fabric (2×2 cm, folded the canvas four times), was placed in a sterilized test tube. Then to it was added 0.1 ml of viral solution for the reaction at room temperature for 60 minutes. After 60 minutes the reaction was added to 1900 ml of protein a nutrient medium with a density of 20 mg/ml for the elution of virus by means of a pipette. Then reactive the sample was diluted with a solution to create minimal supportive environment to 10-2÷10-5(a tenfold serial dilution), and 100 µl of the diluted solutions were sown in MDCK cells, cultured in a Petri dish. After adsorption of virus for 90 minutes was placed on top of a medium with a content of 0.7% agar and the virus was grown in an incubator at a temperature of 34°C in the presence of 5% CO2in the next 48 hours.

After fixing with formalin produced staining with methylene blue, and counted the number of formed plaques to calculate the infectivity titer of the virus (the BATTLE/0.1 ml, Log10) (the BATTLE: blackabyss units) and calculated the infectivity titer of the virus was compared with the index of the control sample.

When using filmy fabric, a sample (5×5 cm) was placed in a sterile plastic Petri dish. Then� in it was added 0.1 ml of viral solution for the reaction at room temperature for 60 minutes. The upper surface of the test specimen was covered with a polypropylene film (4×4 cm) for implementation of the contact between the viral solution and the sample under test. After 60 minutes the reaction was added to 1900 ml of protein a nutrient medium with a density of 20 mg/ml for the elution of virus by means of a pipette. Then we calculated the infectivity titer of the virus (the BATTLE/0.1 ml, Log10) (the BATTLE: blackabyss units).

(Evaluation of antiviral properties in the present invention) Antiviral properties were assessed for each of Examples 1-13 and comparative examples 1-10. The evaluation results are shown in Tables 3 and 4. The values obtained in the conditions when the polypropylene film was not immersed in the solution virus are reference values.

<1
Table 3
The infectivity titer of the virus (the BATTLE/0.1 ml, Log10)
INFLUENZACat calciumvirus
Example 1<1<1
Example 2<1<1
Example 3<1
Example 5<1<1
Example 6<1<1
Example 7<1<1
Example 8<1<1
Example 9<1<1
Example 10<1<1
Example 12<1<1
Comparative example 15.965.45
Comparative example 25.645.62
Comparative example 35.975.60
Comparative example 45.835.81
Comparative example 55.705.79
Comparative example 8 5.645.51
Comparative example 95.815.50
Control sample6.025.95

As can be seen from the above results, the inactivating effect against two types of virus is higher in all the Examples than in the comparative examples. The observed effect was very high, i.e. the percent inactivation after 60 minutes was 99,9999% or more. Thus, provided with a reduced risk of Contracting a viral infection when using such masks.

For a list of reference designations.

1 - base fabric

2 - the virus inactivating fine particles

3 is a silane monomer and oligomer

4 " binder component (a firming agent)

5 - chemical bonding

6 - secondary inorganic fine particles

7 - adhesive

100 virus - inactivating canvas

1. Cloth, inactivating the virus is able to inactivate viruses getting on it, characterized in that it comprises:
the Foundation fabric; and
micronized particles of a compound of monovalent copper and/or fine particles of iodine and micronized particles of a compound of monovalent copper and/or fine particles of iodine applied on the basis of paintings,
moreover, fine particles of compounds of monovalent copper particles are at least one of the following groups: chloride, acetate, sulfide, iodide, bromide, peroxide and thiocynate.

2. The fabric according to claim 1, wherein the thin�dispersed particles of compounds of monovalent copper represent particles, at least one of the following groups: CuCl, CuOOCCH3, CuI, CuBr, Cu2S, and CuSCN.

3. The fabric according to claims.1-2, in which fine particles of iodine compounds represent particles of at least one of the following groups: CuI, AgI, SbI3, IrI4, GeI2, GeI4, SnI2, SnI4, TlI, PtI2, PtI4, PdI2, BiI3, AuI, AuI3, FeI2, CoI2NiI2, Zni extension2, HgI, and InI3.

4. Cloth according to any one of claims.1-2, in which fine particles of compounds of monovalent copper and/or fine particles of iodine retained on the canvas by the group of other inorganic fine particles fixed to the substrate via chemical ring of the silane monomer and/or polymerization product of the silane monomer.

5. Bedspread for the bed, is manufactured using the virus inactivating fabric, according to any of claims.1-4.

6. The protective suit is manufactured using the virus inactivating fabric, according to any of claims.1-4.

7. Gloves, manufactured using the virus inactivating fabric, according to any of claims.1-4.

8. Medical napkin, manufactured using the virus inactivating fabric, according to any of claims.1-4.

9. Medical cap, manufactured using the virus inactivating fabric, according to any of claims.1-4.

10. Shoe covers, manufactured according�made using the virus inactivating paintings according to any one of claims.1-4.

11. The filter is manufactured using the virus inactivating fabric, according to any of claims.1-4.

12. Twill tape, manufactured using the virus inactivating fabric, according to any of claims.1-4.

13. Gauze, manufactured using the virus inactivating fabric, according to any of claims.1-4.

14. Wallpaper, made using the virus inactivating fiber according to any one of claims.1-4.



 

Same patents:

FIELD: veterinary medicine.

SUBSTANCE: vaccine against plague, adenovirus infections, parvovirus and coronavirus enteritis, leptospirosis and rabies of dogs is proposed, containing the active ingredient and targeted additives, characterised in that as the active ingredient it comprises in 1 dose of vaccine the mixture of suspension of attenuated strain of canine distemper virus SCV No. 2313 family Paramyxoviridae, genus Morbillivirus with a titre of at least 103.5 TCD50; suspension of attenuated strain of adenovirus of dogs of type 2 SCV No. 2311, family Adenoviridae, genus Mastadenovirus with a titre of at least 103.0 TCD50; suspension of attenuated strain of canine parvovirus of type 2 SCV No. 2312, family Parvoviridae, genus Parvovirus with a titre of at least 103.0 HAU; suspension of attenuated strain of canine coronavirus SCV No. 2314, family Coronaviridae, genus Coronavirus with a titre of at least 103.0 TCD50; inactivated suspension of strain of rabies of dogs ERA-CB-M20, family Rhabdoviridae, genus Lyssavirus in the amount of 1 ME, inactivated suspensions of leptospira of serogroups Icterohaemorrhagiae and Canicola taken in the mixture in equal proportions with the final concentration of each strain of at least 3×108 inactivated microbial cells in 1 dose of the vaccine.

EFFECT: invention is characterised by higher antigenic and immunogenic potency, safety, ability to create colostral immunity of high intensity, high stability in storage, high specificity in relation to different subtypes and main antigenic variants of epizootic strains of pathogens circulating in the outer environment in the territory of Russia and the CIS countries, the vaccine is environmentally friendly, does not cause dissemination of pathogenic agents.

4 cl, 13 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: composition includes glutaryl histamine in an amount of 18.0-75.0 wt % as an active substance, and as auxiliary substances: microcrystalline cellulose in an amount of 18.0-71.0 wt %, sodium croscarmellose in an amount of 0.25-1.0 wt %, colloidal silicon dioxide in an amount of 0.5-2.0 wt %, calcium stearate in an amount of 0.5-2.0 wt % and lactose monohydrate. The invention also relates to a method of obtaining the said composition.

EFFECT: invention is characterised by the high bioavailability of the active component and high pharmacological activity.

4 cl, 6 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: therapeutic agent contains recombinant interferon specified in a group of: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma, metronidazole, fluconazole and/or voriconazole, and a pharmaceutically acceptable base in the following proportions, g per 1 ml of the mixture: recombinant interferon, international units 100-10,000,000; metronidazole 0.00001-0.5; fluconazole and/or voriconazole 0.00001-0.5; pharmaceutically acceptable base - the rest. Besides, the therapeutic agent contains boric acid in an amount of 0.00001-0.5 g and hypromellose in an amount of 0.00001-0.5 g. As a pharmaceutically acceptable base, it contains macrogol 400 or macrogol 1500, or macrogol 4000.

EFFECT: higher efficacy of the compound.

2 cl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a compound of formula:

,

wherein: each D and Z is independently absent or represents an optionally substituted linear aliphatic group containing zero to eight carbons, wherein 'aliphatic' refers to an alkyl, alkenyl or alkynyl group, and 'optionally substituted' refers to substituting by replacing independently one, two or more hydrogen atoms by substitutes specified in -F, -Cl, -Br, -I, -OH, -NO2, -N3, -CN, -NH2, -NH-C1-C12-alkyl, -NH-C2-C8-alkenyl, -NH-C2-C8-alkynyl, -NH-C3-C12-cycloalkyl, -dialkylamino, -O-C1-C12-alkyl, -NHC(O)-C1-C12-alkyl, -NHC(O)-C2-C8-alkenyl, -NHC(O)-C2-C8-alkynyl, -NHC(O)-C3-C12-cycloalkyl; each A and E is independently absent or represents a cyclic group with the above cyclic group is independently specified in a group consisting of aryl or heteroaryl, each of which is optionally substituted; 'aryl' refers to phenyl, naphthyl, tetrahydronaphthyl, indanyl or idenyl; 'heteroaryl' refers to pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzoxazolyl or quinoxalinyl; 'optionally substituted' refers to substituting by replacing independently one, two, three or more hydrogen atoms by substitutes specified by -F, -Cl, -Br, -I, -OH, -NO2, -N3, -CN, -NH2, -NH-C1-C12-alkyl, -NH-C2-C8-alkenyl, -NH-C2-C8-alkynyl, -NH-C3-C12-cycloalkyl, -dialkylamino, -O-C1-C12-alkyl, -NHC(O)-C1-C12-alkyl, -NHC(O)-C2-C8-alkenyl, -NHC(O)-C2-C8-alkynyl, -NHC(O)-C3-C12-cycloalkyl; T is absent or represents an optionally substituted aliphatic group containing 1 to 24 carbons; 'aliphatic' refers to an alkyl, alkenyl or alkynyl group; 'optionally substituted' refers to substituting substituting by replacing independently one, two, three or more hydrogen atoms by substitutes specified in -F, -Cl, -Br, -I, -OH, -NO2, -N3, -CN, -NH2, -NH-C1-C12-alkyl, -NH-C2-C8-alkenyl, -NH-C2-C8-alkynyl, -NH-C3-C12-cycloalkyl, -dialkylamino, -O-C1-C12-alkyl, -NHC(O)-C1-C12-alkyl, -NHC(O)-C2-C8-alkenyl, -NHC(O)-C2-C8-alkynyl, -NHC(O)-C3-C12-cycloalkyl; one to four of A, D, E, T and Z are absent; the ring B is specified in imidazolyl, pyrazolyl, 1,3,4-thiazolyl, and 1,3,4-oxadiazolyl, and the ring B is bound to J through atom C and bound to Z, E, T, A and D through atom C; in each specific case, R1 is independently specified in a group consisting of hydrogen, halogen, cyano optionally substituted by C1-C4alkyl, -O-R11, -NRaRb, -C(O)R11, -CO2R11 and -C(O)NRaRb; in each specific case, R11 independently represents hydrogen or optionally substituted C1-C8alkyl; in each specific case, each Ra and Rb are independently specified in hydrogen, C1-C8alkyl and C2-C8alkenyl; u is independently equal to 1, 2 or 3; Q and J represent R6 is specified in a group consisting of -C(O)-R12, -C(O)-C(O)-R12, -S(O)2-R12, and -C(S)-R12; in each specific case, R12 is independently specified in a group consisting of -O-R11, -NRaRb, and -R13; and in each specific case, R13 is independently specified in a group consisting of: hydrogen, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, C3-C8cycloalkyl and C3-C8cycloalkenyl, each of which is optionally substituted; 'optionally substituted' refers to substituting independently by replacing one, two, three or more hydrogen atoms by substitutes specified in -F, -Cl, -Br, -I, -OH, -NO2, -N3, -CN, -NH2, -NH-C1-C12-alkyl, -NH-C2-C8-alkenyl, -NH-C2-C8-alkynyl, -NH-C3-C12-cycloalkyl, -dialkylamino, -O-C1-C12-alkyl, -NHC(O)-C1-C12-alkyl, -NHC(O)-C2-C8-alkenyl, -NHC(O)-C2-C8-alkynyl, -NHC(O)-C3-C12-cycloalkyl, which inhibit an RNA-containing virus, particularly hepatitis C virus (HCV).

EFFECT: preparing hepatitis C inhibitors.

38 cl, 22 tbl, 516 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of structural formula (I), which possess the properties of HCV polymerase inhibitors. In formula , is specified in a group consisting of a single carbon-carbon bond and a double carbon-carbon bond; R1 and R3 are specified in hydrogen and methyl; R2 represents hydrogen; R5 is specified in a group consisting of hydrogen, hydroxy, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkoxy, C2-C6alkenyloxy, C3-C6alkynyloxy and halo; L represents a bond, and R6 represents a condensed 2-ring carbocyclyl, wherein each substitute is optionally substituted by one or more substitutes independently specified in a group consisting of RE, RF, RG, RH, RI, RJ and RK; or L is specified in a group consisting of a bond, C≡C, C(O)N(RC), N(RD)C(O), C1-C2-alkylene, C(H)2O, OC(H)2, cyclopropyl-1,2-ene, C(H)2N(RL), N(RM)C(H)2, C(O)CH2 and CH2C(O), and R6 is specified in a group consisting of C5-C6-carbocyclyk and 5-6-merous heterocyclyl, wherein each substitute is optionally substituted by one or more substitutes independently specified in a group consisting of RE, RF, RG, RH, RI, RJ, RK, RL and RM; the R4, RE, RF, RG, RH, RI, RJ, RK, RL and RM values are presented in the patent claim.

EFFECT: invention refers to a pharmaceutical composition containing the above compounds, to using the compounds for producing a drug preparation for HCV RNA polymerase inhibition and hepatitis C treatment, and to a method for preparing the above compounds.

21 cl, 46 dwg, 42 tbl, 140 ex

FIELD: medicine.

SUBSTANCE: invention refers to a medicated product based on a chemical compound of 7-[N'-(4-trifluoromethylbenzoyl)-hydrazinocarbonyl]-tricyclo[3.2.2.02,4]non-8-ene-6-carboxylic acid (NIOH-14, N.N. Vorozhtsov Novosibirsk Institute Of Organic Chemistry) in a dose of 4 to 60 mg/kg of body weight, possessing the anti-smallpox virus activity, as well as a method for producing and using for the smallpox virus for preventing and treating mammals involving oral administration once a day in a dose range from 4 to 60 mg/kg of the mammalian body weight. A method for producing the medicated product possessing the anti-smallpox virus activity involves diluting and performing a reaction of 4-trifluorobenzoic acid hydrazide and 3,3a,4,4a,5,5a,6.6a-octahydro-1,3-dioxo-4,6-etheno-cycloprop[f]-furane in a molar ratio of 1:1 in a solvent and mixing the produced suspension until producing sediments which are removed from the solution, filtered and dried to produce an end product that is a chemical compound of 7-[N'-(4-trifluoromethylbenzoyl)-hydrazinocarbonyl]-tricyclo[3.2.2.02,4]non-8-ene-6-carboxylic acid (NIOH-14, N.N. Vorozhtsov Novosibirsk Institute Of Organic Chemistry). The solvent is ethyl or isopropyl alcohol; preparing the suspensions, separating and filtering the sediments are performed at a temperature of +2-10°C, while a dry product yield makes 96.0%.

EFFECT: invention provides the less toxic preparation of the medicated product, possessing the high anti-smallpox virus activity.

4 cl, 4 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention provides an agent for arresting undesirable vaccinal reactions and complications during primary vaccination with variolar vaccines, characterised by that it contains 7-[N'-(4-trifluoromethylbenzoyl)-hydrazine-carbonyl]-tricyclo[3.2.2.02,4]non-8-ene-6-carboxylic acid, and a method of using said agent in doses of 3.3-50 mg/kg body mass once a day on the day of vaccination and two days after vaccination, which does not reduce potency of the vaccine.

EFFECT: arrests undesirable vaccinal reactions and complications during primary vaccination with variolar vaccines.

2 cl, 5 ex, 4 tbl

Antiviral agent // 2542488

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to an antiviral agent and aims at inactivating a wide range of viruses. The antiviral agent contains an active agent presented by particles of at least one type of iodide formed by iodine and an element formed in 4-6th periods of the 8-10th or 12-15th groups of the periodic table, Cu or Au. The above element found in the 4-6th periods of the 8-10th or 12-15th groups of the periodic table represents Sb, Ir, Ge, Sn, Tl, Pt, Pd, Bi, Fe, Co, Ni, Zn, In or Hg. What is also presented is the antiviral agent containing particles of at least one type of a cuprous compound as an active ingredient. The above cuprous compound represents chloride, acetate, sulphide, iodide, bromide, peroxide, oxide or thiocyanide.

EFFECT: using the group of inventions provides the agent having the high antiviral activity; the above agent is able to exhibit and maintain its antiviral activity easily since it requires no preparation or special washing.

5 cl, 4 tbl, 27 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of structural formula I, their pharmaceutically acceptable salts and crystalline forms, which possess the properties of HCV polymerase inhibitor. In formula I is specified in a group consisting of a single carbon-carbon bond and a double carbon-carbon bond; R1 represents hydrogen; R2 is specified in a group consisting of hydrogen and halo; R3 represents hydrogen; R4 is specified in a group consisting of halo, C1-C6alkyl, C1-C6alkylsulphonyl and 5-6-merous heteroaryl containing heteroatom specified in N, O and S, wherein alkyl is optionally substituted by one or more hydroxy; R5 is specified in a group consisting of hygrogen, hydroxy, C1-C6alkyloxy and halo; L is specified in a group consisting of C(RA)=C(RB), ethylene and cyclopropyl-1,2-ene; RA and RB are independently specified in a group consisting of hydrogen, C1-C6alkyl, C1-C6alkyloxy and halo; R6 represents C6aryl optionally substituted by one or more substitutes independently specified in a group consisting of RE, RF, RG, RH, RI and RJ; the substitutes RE, RF, RG, RH, RI and RJ are presented in the patent claim.

EFFECT: invention refers to the pharmaceutical composition containing the above compounds, to using the compounds for inhibiting HCV RNA-polymerase and treating hepatitis C and to a method of preparing the above compounds.

40 cl, 23 dwg, 7 tbl, 40 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: presented inventions refer to a lyophilised composition for inducing an immune response to flavivirus, compositions for preparing the above lyophilised composition, and a method for preparing the lyophilised composition. The characterised lyophilised composition contains an effective amount of live attenuated flavivirus, one or more stabilising agents, one or more buffer components, lactose and amorphous mannitol, which is prepared by lyophilising mixture containing an effective amount of live attenuated flavivirus, one or more stabilising agents, one or more buffer components, lactose and mannitol; flavivirus can be chimeric flavivirus. Preparing the above lyophilised composition involves freezing the components and drying them thereafter.

EFFECT: inventions enable preparing the transportation and storage stable compositions containing flavivirus.

31 cl, 13 dwg, 10 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: what is described is an antiseptic sorption material having the anti-inflammatory, wound-healing, absorbent, astringent and antiseptic action representing a microfiber matrix with a disperse adsorbent attached to its fibres and containing highly porous alumina hydrate particles and zinc oxide particles. A method for making the same and a based dressing are also described.

EFFECT: material is applicable for making wound dressings having additional functional properties and maintaining the absorbing properties of the material absorbing the wound discharge, inhibiting bacterial growth inside the dressing and preventing the wound re-infection.

15 cl, 4 dwg, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: what is described is a bioactive wound coating of a hydrogel nanocomposite, which contains antimicrobial and antioxidant ingredients: silver-modified montmorillonite and fullerenol used to optimise the clinical course of the wound process, to prevent and suppress a wound infection. The wound coating can be used to treat gun-shot injuries, severe mechanical injuries, infected and uninfected wounds, including septic and persistent, granulating wounds following deep thermal, chemical and radioactive burns, in the combined therapy of trophic ulcers and bed sores at hospital, in the outpatient setting and in the field. The wound coating is elastic, not fragmented in dressing that facilitates wound care. A high sorption ability of the wound coating matrix, including of coarse-molecular ingredients of the wound effluent, provides the fast elimination of the wound bed. Using the hydrogel, i.e. possessing high degree of hydration, the wound coating meets the modern wound management in the humid medium.

EFFECT: optimum conditions for the early activation of the repair processes.

5 dwg, 2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: what is described is a mesh bioactive wound coating with its base containing disintegrated bacterial cellulose comprising antimicrobial and antioxidant ingredients: silver-modified montmorillonite and fellerenol aiming at optimising the course of the wound process, preventing the development and suppression of a wound infection. The mesh bioactive wound coating is used for treating gunshot wounds, severe mechanical injuries, uninfected and infected wounds, including septic and persistent wounds, granulating wounds following deep thermal, chemical and radiation burns, for conducting the integrated treatment of trophic ulcers and bedsores in hospital, out-patient and field settings.

EFFECT: mesh bioactive wound coating is non-toxic; it causes no local irritant and skin re-absorption action, possesses elasticity, a high degree of wound modelling; it is not fragmented that facilitates a wound care.

5 dwg, 2 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: method of obtaining films based on polyvinyl alcohol with nanostructured silver includes obtaining silver nanoparticles, their combination with polyvinyl alcohol and formation of film. Silver nanoparticles of required size are obtained by mixing water solutions of silver nitrate and L-cysteine in molar ratio 1.25-2.00. Combination of silver nanoparticles with polyvinyl alcohol is carried out in 10-12 wt % water solution of polyvinyl alcohol at temperature 85-90°C and volume ratio of mixed solutions 1:1 with obtaining supramolecular polymer. Obtained films can be applied in medicine, in particular in surgery for treatment of wounds, burns, injuries as minimal traumatic, biocompatible and biosoluble, antimicrobial bandages for injured skin.

EFFECT: increased application efficiency.

2 cl, 1 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a copper-bearing cellulosic material possessing the fungicidal, bactericidal and deodorant properties, containing a cellulose matrix coated with copper particles prepared by chemical reduction of copper ions absorbed in the cellulose matrix, differing by the fact that the copper ions absorbed in the cellulose matrix are reduced in micelle solution of a cationic surfactant; the material contains copper and copper oxide nanoparticles with the size of 5-19 nm and has a composition as follows, wt %: cellulose matrix 99.5-98.0, copper nanoparticles 0.5-2.0.

EFFECT: said materials can find application in manufacturing sanitary products.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, more specifically to dressings used in general surgery, traumatology, obstetrics, gynaecology, proctology, dentistry for closure and healing of wounds (including post-operative), bed-sores, ulcers, burns, complicated purulent and putrid infections with an evident purulo-necrotic layer. A wound and burn closure and healing dressing containing a wound or burn facing therapeutic layer consisting of a therapeutic and sorption agent that is a layer of paste-like gel of iron or aluminium gel with added graphite carbon at 1 g of the additive per 100 ml of the gel, of the thickness of 0.5 cm providing a sorption ability not less than 10 g/g.

EFFECT: preparing the wound and burn dressing possessing high antimicrobial activity and analgesic characteristics, improved sorption ability and atraumatic properties.

7 tbl, 23 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine. What is described is a composite material which contains a non-organic substance in the form of a layer or a layer ingredient with the non-organic substance leads to form hydrogen cations in contact with an aqueous medium that induces an antimicrobial effect with the substance being produced of MoO2, MoO3, molybdenum carbide, molybdenum nitride, molybdenum silicide, molybdenum sulphide, molybdenum hexacarbonyl and/or molybdenum acetylacetonate.

EFFECT: antimicrobial effect of the composite material is found through time almost with no limit.

32 cl, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, more specifically to chemical-pharmaceutical industries and medical equipment. What is described is a fixer representing an adhesive tape consisting of paper base 45-55 g/m and a pressure sensitive adhesive coating one of the base sides. The adhesive layer is protected by siliconised paper.

EFFECT: agent provides higher adhesive properties, better vapour permeability, does not irritate skin, possess higher viability.

5 cl, 2 tbl

Corn plaster // 2454249

FIELD: medicine.

SUBSTANCE: invention refers to medical and chemical-pharmaceutical industry and is applicable in healthcare facilities and domiciliary for external application as a remedy in skin diseases: corns, plantar callosities, callules. A corn plaster contains salicylic acid, precipitated sulphur, anhydrous lanolin, pine rosin, lump rubber, dimethylsulphoxide, pine resion, petrolatum and agidol with salicylic acid used as micronised particles sized max. 30 mcm, and the ingredients taken in certain proportions. The experimental clinical findings have shown that the leukocytic mass applied on corns has an effect on adjoining skin areas causing no allergy, irritation or redness if the plaster is applied on healthy skin.

EFFECT: corn plaster improves keratolytic, antiseptic and antimycotic properties ensured by qualitative and quantitative composition of the ingredients.

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is described is a haemostatic device for blood coagulation improvement which contains a gauze base, a clay material located thereon, and also polyol, such as glycerol or similar placed on the gauze base for binding the clay material. The device for bleeding wound management comprises at least a portion of the clay material contacting to blood flowing from the wound to cause coagulation. A dressing applicable on the bleeding wound for blood coagulation improvement comprises a flexible base and a gauze base located thereon. The gauze base comprises the clay material and polyol. Ahaemostatic sponge also contains a gauze basis and a disperse system of the haemostatic material and polyol on the first base surface. The invention also refers to N-substituted monomers and polymers, methods for producing such monomers and polymers and to methods for using for various medical purposes, e.g. in medical devices. In the preferential versions, a medical device represents a stent.

EFFECT: haemostatic device improves blood coagulation.

43 cl, 1 tbl, 9 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to gastroenterology, and can be used for the treatment of chronic constipation and functional anorexia. For this purpose, as medicinal nutrition used is a milk-vitamin mixture with the following composition (g per 100 g of the product): Proteins 24-26, Fats 27-29, Carbohydrates 33-34, minerals (mg per 100 g of the product), calcium 940-970, phosphorus 780-820, sodium 230-270, potassium 1370-1550, chloride 1270-1350, magnesium 100-125, iron 9.5-10.7, zinc 2.7-3.5, iodine 145-173, copper 76-87, manganese 45-52, vitamins (mcg per 100 g of the product) D3 7.6-8.2, E 6.2-6.8, C 42-46, B1 960-990, B2 1150-1250, Niacin11-15, B6 1370-1440, Folic acid 125-150, Pantothenic acid 2250-2370, B12 1.5-1.9, Biotin 25-31, Choline 40-45.

EFFECT: invention provides an increase of treatment efficiency.

3 ex

Up!
[Table 4]
The infectivity titer of the virus (the BATTLE/0.1 ml, Log10)
INFLUENZACat calciumvirus
Example 4<1<1
Example 11<1<1
Example 13<1<1
Comparative example 66.015.40
Comparative example 75.845.90
Comparative example 105.705.76
Control sample6.025.95